Mainstream

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) —

You might also be interested in reading Blockchain games take on the mainstream: Here’s how they can win.

March 26, 2025
In Mainstream